# US 2026/0216406 A1 · Devices and methods of a medicament-producing implantable matrix

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216406 A1
- Document ID: US20260216406A1
- Status: Published application
- Kind: A1
- Application number: 19/146,748
- Filed: 2024-01-11
- Published: 2026-07-30
- Earliest claimed: 2023-01-11
- Assignees: Humacyte Global, Inc.
- Applicants: Humacyte Global, Inc.
- Inventors: Mehmet H. KURAL; Kaleb NAEGELI; Hong QIAN; Yuling LI; Laura E. NIKLASON
- Web page: https://patentgrep.com/patent/US20260216406A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/222: {Gelatin}
- A61L 27/44: having a macromolecular matrix
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 2400/06: Flowable or injectable implant compositions
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Described herein are variations of a medicament-producing implantable matrix for the treatment of chronic diseases. For example, an implantable matrix may include a cell-coated a human acellular vessel-based vascular graft. The cells may be engineered to produce medicaments capable of treating a chronic disease. A cell-seeded matrix may be implanted adjacent to a patient's blood vessel such that the medicaments produced by the cells are easily released into the patient's blood stream. Additionally, or alternatively, a cell-seeded matrix may treat chronic disease at an environment local to an implantation site. Also described herein are methods for making and use of such implantable matrices.

## Claims

### Claim 1

A medicament-producing implantable matrix comprising a matrix comprising at least one population of cells.

### Claim 2 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells produces one or more drug molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a.

### Claim 3 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 4 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells produces interleukin-10.

### Claim 5 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 6 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 7 (depends on 1)

The implantable matrix of claim 1, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 8 (depends on 1)

The implantable matrix of claim 1, wherein the matrix comprises at least one selected from the group consisting of: a hydrogel and a biodegradable polymer.

### Claim 9 (depends on 1)

The implantable matrix of claim 1, wherein the matrix comprises a Fas receptor activating molecule.

### Claim 10 (depends on 9)

The implantable matrix of claim 9, wherein the Fas receptor activating molecule comprises a Fas ligand.

### Claim 11 (depends on 1)

The implantable matrix of claim 1, wherein the matrix comprises a hydrogel comprising thrombin and fibrinogen.

### Claim 12 (depends on 11)

The implantable matrix of claim 11, wherein the thrombin is at a concentration of between about 0.1 units/mL and about 100 units/mL.

### Claim 13 (depends on 11)

The implantable matrix of claim 11, wherein the fibrinogen is at a concentration of between about 3 units/mL and about 100 units/mL.

### Claim 14 (depends on 1)

The implantable matrix of claim 1, wherein the matrix is implanted into at least one body region of a patient selected from the group consisting of: arms, legs, knees, hips, elbows, wrists, spine, stomach, blood vessels, and intestines.

### Claim 15 (depends on 1)

The matrix of claim 1, wherein the matrix can be formed in the desired implantation site by injecting the cells in a hydrogel glue solution.

### Claim 16 (depends on 8)

The implantable matrix of claim 8, wherein the biodegradable polymer is one selected from the group consisting of: polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, poly(caprolactone).

### Claim 17 (depends on 8)

The implantable matrix of claim 8, wherein the hydrogel is at least one of a naturally-derived hydrogel and a synthetic hydrogel.

### Claim 18

A medicament-producing implantable matrix, comprising:
a frame comprising collagen; and
a matrix comprising at least one population of cells, wherein the matrix is at least one of attached to and within the frame.

### Claim 19 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a

### Claim 20 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 21 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells produces interleukin-10.

### Claim 22 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 23 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 24 (depends on 18)

The implantable matrix of claim 18, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 25 (depends on 18)

The implantable matrix of claim 18, wherein the matrix comprises at least one selected from the group consisting of: a hydrogel and a biodegradable polymer.

### Claim 26 (depends on 25)

The implantable matrix of claim 25, wherein the biodegradable polymer is one selected from the group consisting of: polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, poly(caprolactone).

### Claim 27 (depends on 25)

The implantable matrix of claim 25, wherein the hydrogel is at least one of a naturally-derived hydrogel and a synthetic hydrogel.

### Claim 28 (depends on 18)

The implantable matrix of claim 18, wherein the matrix comprises a hydrogel comprising thrombin and fibrinogen.

### Claim 29 (depends on 28)

The implantable matrix of claim 28, wherein the thrombin is at a concentration of between about 0.5 units/mL and about 100 units/mL.

### Claim 30 (depends on 28)

The implantable matrix of claim 28, wherein the fibrinogen is at a concentration of between about 3 units/mL and about 100 units/mL.

### Claim 31 (depends on 18)

The implantable matrix of claim 18, wherein the matrix is implanted into at least one body region of a patient selected from the group consisting of: arms, legs, knees, hips, elbows, wrists, spine, stomach, blood vessels, and intestines.

### Claim 32

A method of forming a medicament-producing implantable matrix, comprising:
combining at least one population of cells with a solubilized matrix;
casting the combination into a frame; and
polymerizing the solubilized matrix.

### Claim 33 (depends on 32)

The implantable matrix of claim 32, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a.

### Claim 34 (depends on 32)

The implantable matrix of claim 32, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 35 (depends on 32)

The method of claim 32, wherein the at least one population of cells produces interleukin-10.

### Claim 36 (depends on 32)

The method of claim 32, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 37 (depends on 32)

The method of claim 32, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 38 (depends on 32)

The method of claim 32, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 39 (depends on 32)

The method of claim 32, wherein the matrix comprises at least one selected from the group consisting of: a hydrogel and a biodegradable polymer.

### Claim 40 (depends on 39)

The method of claim 39, wherein the biodegradable polymer is one selected from the group consisting of: polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, poly(caprolactone).

### Claim 41 (depends on 39)

The method of claim 39, wherein the hydrogel is at least one of a naturally-derived hydrogel and a synthetic hydrogel.

### Claim 42 (depends on 32)

The implantable matrix of claim 32, wherein the matrix comprises a Fas receptor activating molecule.

### Claim 43 (depends on 42)

The implantable matrix of claim 42, wherein the Fas receptor activating molecule comprises a Fas ligand.

### Claim 44 (depends on 32)

The method of claim 32, wherein the matrix comprises a hydrogel comprising thrombin and fibrinogen.

### Claim 45 (depends on 44)

The method of claim 44, wherein the thrombin is at a concentration of between about 0.5 units/mL and about 100 units/mL.

### Claim 46 (depends on 44)

The method of claim 44, wherein the fibrinogen is at a concentration of between about 3 units/mL and about 100 units/mL.

### Claim 47 (depends on 32)

The method of claim 32, wherein the matrix is implanted into at least one body region of a patient selected from the group consisting of: knees, hips, elbows, wrists, spine, stomach, and intestines.

### Claim 48

An apparatus, comprising:
a tubular support graft comprising a matrix and at least one population of cells, wherein the tubular support graft is configured to be concentrically positioned around a tubular vascular graft.

### Claim 49 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a.

### Claim 50 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 51 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells produces interleukin-10.

### Claim 52 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 53 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells comprises monocytes.

### Claim 54 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 55 (depends on 48)

The apparatus of claim 48, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 56 (depends on 48)

The apparatus of claim 48, wherein the matrix comprises at least one selected from the group consisting of: a hydrogel and a biodegradable polymer.

### Claim 57 (depends on 56)

The apparatus of claim 56, wherein the biodegradable polymer is one selected from the group consisting of: polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, poly(caprolactone).

### Claim 58 (depends on 56)

The apparatus of claim 56, wherein the hydrogel is at least one of a naturally-derived hydrogel and a synthetic hydrogel.

### Claim 59 (depends on 48)

The implantable matrix of claim 48, wherein the matrix comprises a Fas receptor activating molecule.

### Claim 60 (depends on 48)

The implantable matrix of claim 48, wherein the Fas receptor activating molecule comprises a Fas ligand.

### Claim 61 (depends on 48)

The apparatus of claim 48, wherein the matrix comprises a hydrogel comprising thrombin and fibrinogen.

### Claim 62 (depends on 61)

The apparatus of claim 61, wherein the thrombin is at a concentration of between about 0.5 units/mL and about 100 units/mL.

### Claim 63 (depends on 61)

The apparatus of claim 61, wherein the fibrinogen is at a concentration of between about 3 units/mL and about 100 units/mL.

### Claim 64 (depends on 48)

The apparatus of claim 48, wherein the tubular support graft is formed by one of molding, casting, planar tissue culture, electrospinning, and 3-dimensional printing.

### Claim 65 (depends on 48)

The apparatus of claim 48, wherein a length of the tubular support graft is less than a length of the tubular vascular graft.

### Claim 66 (depends on 48)

The apparatus of claim 48, wherein a length of the tubular support graft is greater than a length of the tubular vascular graft.

### Claim 67 (depends on 48)

The apparatus of claim 48, wherein a length of the tubular vascular graft is between 1 cm and 100 cm.

### Claim 68

An apparatus, comprising:
a tubular support graft, wherein the tubular support graft is configured to be concentrically positioned around a vascular graft; and
a matrix comprising at least one population of cells and disposed on an external surface of the tubular support graft.

### Claim 69 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a

### Claim 70 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 71 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells produces interleukin-10.

### Claim 72 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 73 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 74 (depends on 68)

The apparatus of claim 68, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 75 (depends on 68)

The apparatus of claim 68, wherein the tubular support graft comprises one or more selected from the group consisting of: fibrin, collagen, alginate, gelatin, chitosan, dextran, hyaluronic acid, or PEG.

### Claim 76 (depends on 68)

The apparatus of claim 68, wherein the tubular support graft comprises a combination of: PEG and chitosan, PEG and gelatin, PEG and hyaluronic acid, PAM and gelatin, or PVA and gelatin.

### Claim 77 (depends on 68)

The apparatus of claim 68, wherein the matrix comprises at least one selected from the group consisting of: a hydrogel and a biodegradable polymer.

### Claim 78 (depends on 77)

The apparatus of claim 77, wherein the biodegradable polymer is one selected from the group consisting of: polyglycolic acid, polylactic acid, poly(lactic-co-glycolic) acid, poly(caprolactone).

### Claim 79 (depends on 77)

The apparatus of claim 77, wherein the hydrogel is at least one of a naturally-derived hydrogel and a synthetic hydrogel.

### Claim 80 (depends on 68)

The apparatus of claim 68, wherein the matrix comprises a hydrogel comprising thrombin and fibrinogen.

### Claim 81 (depends on 80)

The apparatus of claim 80, wherein the thrombin is at a concentration of between about 0.5 units/mL and about 100 units/mL.

### Claim 82 (depends on 80)

The apparatus of claim 80, wherein the fibrinogen is at a concentration of between about 3 units/mL and about 100 units/mL.

### Claim 83 (depends on 68)

The apparatus of claim 68, wherein the tubular support graft is formed by one of molding, casting, planar tissue culture, electrospinning, and 3-dimensional printing.

### Claim 84 (depends on 68)

The apparatus of claim 68, wherein a length of the tubular support graft is less than a length of the tubular vascular graft.

### Claim 85 (depends on 68)

The apparatus of claim 68, wherein a length of the tubular support graft is greater than a length of the tubular vascular graft.

### Claim 86 (depends on 68)

The apparatus of claim 68, wherein a length of the vascular graft is between 1 cm and 100 cm.

### Claim 87

A method for forming a functionalized tubular support graft for a vascular graft, comprising:
mounting a tubular support graft to a support mandrel;
rotating the support mandrel at a predetermined speed;
depositing, via a 3-dimensional printer, droplets of a mixture of hydrogel and at least one population of cells onto an external surface of the tubular support graft; and
after curing, removing the functionalized tubular support graft from the support mandrel.

### Claim 88 (depends on 87)

The method of claim 87, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Ocrelizumab, Natalizumab, Pembrolizumab, Infliximab, Vedolizumab, Dabrafenib, Lecanemab, or interferon beta-1a.

### Claim 89 (depends on 87)

The method of claim 87, wherein the at least one population of cells produces one or more molecules selected from the group consisting of: Factor VII, Factor VIII, Factor IX, Factor X, Von Willebrand factor, Protein C, human albumin, human Immune Globulin, testosterone, human Htt, or P42.

### Claim 90 (depends on 87)

The method of claim 87, wherein the at least one population of cells produces interleukin-10.

### Claim 91 (depends on 87)

The method of claim 87, wherein the at least one population of cells produces one or more of a sirolimus or a tacrolimus.

### Claim 92 (depends on 87)

The method of claim 87, wherein the at least one population of cells comprises monocytes.

### Claim 93 (depends on 87)

The method of claim 87, wherein the at least one population of cells comprises mesenchymal stem cells.

### Claim 94 (depends on 87)

The method of claim 87, wherein the at least one population of cells comprises major histocompatibility complex class I and II knock-out mesenchymal stem cells.

### Claim 95 (depends on 87)

The apparatus of claim 87, wherein the tubular support graft comprises one or more selected from the group consisting of: fibrin, collagen, alginate, gelatin, chitosan, dextran, hyaluronic acid, or PEG.

### Claim 96 (depends on 87)

The apparatus of claim 87, wherein the tubular support graft comprises a combination of: PEG and chitosan, PEG and gelatin, PEG and hyaluronic acid, PAM and gelatin, or PVA and gelatin.

### Claim 97 (depends on 87)

The method of claim 87, further comprising, implanting the vascular graft of the functionalized tubular support graft into an arm of a patient.

### Claim 98 (depends on 87)

The method of claim 87, further comprising, implanting the vascular graft of the functionalized tubular support graft adjacent to an artery of a patient.

### Claim 99 (depends on 87)

The method of claim 87, wherein the vascular graft can comprises one or more selected from the group consisting of: fibrin, collagen, alginate, gelatin, chitosan, dextran, hyaluronic acid, or PEG.

### Claim 100 (depends on 87)

The method of claim 87, wherein the vascular graft can comprises a combination of: PEG and chitosan, PEG and gelatin, PEG and hyaluronic acid, PAM and gelatin, or PVA and gelatin.

### Claim 101 (depends on 87)

The method of claim 87 further comprising placing the tubular support graft on an outer surface of the vascular graft.
